{"status":"success","data":{"title":"Ectopic Pregnancy and Methotrexate","slug":"ectopic-methotrexate","tags":["Methotrexate,"],"collection":["OBGYN"],"content":"\n# Ectopic Pregnancy and Methotrexate\n\n-   2% of all first-trimester pregnancies and 6% of all pregnancy-related deaths\n-   18% of patients who present with first-trimester bleeding or abdominal pain in the Emergency Department\n-   Risk factors\n\n  - Prior tubal, pelvic, or abdominal surgery\n  - Genital infections leading to pelvic inflammatory disease\n  - Prior ectopic pregnancy\n  - In utero exposure to diethylstilbestrol (DES)\n  - History of infertility\n  - Use of assisted reproductive technologies (in vitro fertilization)\n  - Tobacco use\n\n## Methotrexate (MTX)\n\n**Background**\n\n-   Dihydrofolate reductase inhibitor\n-   Overall success rate for treating ectopic pregnancy = 71-94%\n-   Success rate of single-dose MTX for B-hCG &gt; 5,000 mIU/mL = 85.7% \n\n**Side Effects**\n-   Abdominal pain\n-   Nausea/vomiting\n-   Stomatitis    \n\n## Eligibility / Contraindications for MTX in Ectopic Pregnancy\n\n**Eligibility Criteria:**\n\n-   High clinical suspicion or confirmed ectopic pregnancy,\n-   Hemodynamically stable,\n-   Unruptured mass,\n-   Able to comply with close follow-up, **AND**\n-   Normal creatinine, liver transaminases, WBC, hematocrit, and platelet counts \n\n**Contraindications:**\n-   Breastfeeding\n-   Overt or lab evidence of immunodeficiency\n-   Alcoholism, alcoholic or chronic liver disease\n-   Preexisting blood dyscrasias or significant anemia \n-   Known sensitivity to MTX\n-   Active pulmonary disease\n-   Peptic ulcer disease\n-   Hepatic, renal, or hematologic dysfunction\n-   Gestational sac &gt; 3.5 cm on U/S (relative contraindication) \n-   Embryonic cardiac motion on U/S (relative contraindication) \n\n## Single-Dose Regimen\n\n-   <span class=\"drug\">Methotrexate</span> 50 mg/m2 IM on Day 1\n\n**Follow up with obstetrician to:**\n-   Measure B-hCG on Days 4 and 7\n-   Check for 15% B-hCG decrease between days 4 and 7\n-   Measure B-hCG weekly until non-pregnant level\n-   If B-hCG dose not decrease by &gt;15% as expected, re-dose 50 mg/m2 IM and repeat B-hCG on days 4 and 7 after 2nd dose. \n\n## Alternative Regimens\n\n-   **Two-Dose** and **Fixed Multidose** regimens available as proposed by ACOG guidelines - Consider for B-hCG level &gt; 5,000 mIU/mL\n\n## References\n\n-   [ACOG Practice Bulletin No. 94:Medical management of ectopic pregnancy. Obstet Gynecology. 2008; 111(6):1479-85.](http://www.ncbi.nlm.nih.gov/pubmed/18515537)\n"}}